Clinical Trial – Skin Cancer Pill ‘Doubles Length of Survival’
Source: Stephen Adams Medical Correspondent
The Telegraph – UK
A twice-daily pill has been found to almost double the length of time that patients with advanced skin cancer can survive.
UCLA's Dr. Antoni Ribas
A clinical trial of 132 people with metastatic melanoma, found that on average they lived for almost 16 months when put on the drug, called vemurafenib.
By comparison, those with skin cancer that has already spread to other organs who are put on standard treatments tend to live for between six and 10 months after diagnosis, according to the researchers, writing in the New England Journal of Medicine (NEJM).
Dr Antoni Ribas, professor of hematology and oncology at the University of California, Los Angeles, said: “We knew this drug would make the melanomas shrink in a large proportion of patients and that it worked better than chemotherapy. We did not know that patients taking Zelboraf were living longer until now.”
However, it only works in those with a mutation of the BRAF gene called V600, present in about half of melanomas.
Tumors eventually became resistant to the drug, while side effects include photosensitivity, fatigue, and alopecia. A quarter of patients also develop secondary skin cancers, which have to be removed surgically.
The drug, marketed as Zelboraf by makers Roche, was recommended for approval last month by the European Medicines Agency. It has yet to be examined for clinical and cost effectiveness by the National Institute for Health and Clinical Excellence (Nice).
Every year, some 11,700 people are diagnosed with malignant melanoma inBritain. Of those who do not have them removed before the cancer spreads to other parts of the body, only about a quarter survive longer than a year. The disease claims 2,000 lives a year in the UK.
More than half of those on Zelboraf / vemurafenib in the study (58 per cent) lived longer than 12 months.
About SIMSYS-MoleMate
The FDA approved SIMSYS-MoleMate Skin Imaging System, a non-invasive skin cancer screening procedure, is a significant advance in the early detection of potentially life threatening moles and lesions.
Physicians have found the SIMSYS-MoleMate Siascope hand-held device easy to learn and use, and that it rapidly provides accurate images of the pigment, blood, and collagen below the mole or lesion.
Now, for the first time, physicians can more accurately evaluate suspicious moles and lesions in a non-invasive, pain-free way. Experts also believe it may reduce the need for time consuming and expensive biopsies.
For more information about SIMSYS-MoleMate, contact:
MedX Health Corp.
(905) 670-4428
(888) 363-3112
info@medxhealth.com
www.simsys-molemate.com
